Covalon Technologies (COV) Q3 2024 earnings summary

Executive summary

• Q3 2024 delivered strong results with revenue of $9.2 million, up 47% year-over-year, and gross profit of $5.4 million, up 51% year-over-year, reflecting sustained profitability and operational turnaround.

• Adjusted EBITDA reached $2.4 million, a significant improvement from a loss a year ago, and EPS was $0.06, highlighting operational improvement.

• US market accounted for 87% of total revenue, with US product sales driving 90% year-over-year growth and international revenue remaining flat due to tender-based lumpiness.

• Two consecutive quarters of net income and strong customer retention signal a successful turnaround and foundation for future growth.

• Management highlighted progress on key priorities, improved margins, and disciplined operating expenses.

Financial highlights

• Q3 revenue grew to $9.2 million from $6.3 million in Q3 FY'23 (+47.1%), with gross margin improving to 58.9% and adjusted gross margin reaching 64%.

• Operating expenses decreased year-over-year, supporting higher revenue and improved profitability.

• Net income for Q3 was $1.45 million, compared to a net loss of $0.5 million in the prior year; EPS improved from a loss of $0.02 to $0.06.

• Year-to-date revenue reached $22.3 million (+13.2% YoY), with US product revenue up 63% and coatings business down $2 million.

• Cash position increased to $9.4 million in Q3 FY'24, with zero debt and a current ratio of 5.2.

Outlook and guidance

• Management expects strong growth to continue through the end of 2024 and into 2025, focusing on commercial growth, product improvements, and international expansion.

• Focus remains on retaining existing customers, growing share of wallet, and acquiring new customers, especially in the US hospital market.

• Strategic priorities are organized into immediate commercial growth, mid-term product and market development, and long-term innovation and international expansion.

• Forward-looking statements caution about risks and uncertainties that could impact future results.